Age | Sex | Mutation | Dominant clinical features and the Reasons for Discontinuation of Anti-IL1 Treatment | Duration of Using Anti-IL-1 agents | Recent treatments/conditions | ||
---|---|---|---|---|---|---|---|
Patient 1 | 21 | F | M694 V homozygous | Amyloidosis Stage 5 CRD 11 g/day proteinuria | İncrease of proteinuria, Progression of CRD | Anakinra/12 months | Renal tx |
Patient 2 | 28 | M | M694 V heterozygous M680I heterozygous | PAN+sacroiliitis | Activation of PAN/high dose corticosteroid | Anakinra/12 months | Sepsis-died |
Patient 3 | 25 | M | M694 V heterozygous M680I heterozygous | Sacroiliitis | refractory low back pain high BASDAI score | Canakinumab/4 months | Anti-TNF |
Patient 4 | 24 | M | M694 V homozygous | Sacroiliitis | refractory low back pain high BASDAI score | Canakinumab/6 months | Anti-TNF |
Patient 5 | 50 | M | R761H homozygous | Sacroiliitis+polyarthritis | Refractory arthritis | Canakinumab/18 months (secondary non-responder) | Tocilizumab |
Patient 6 | 19 | M | M680I homozygous | Peripheral Arthritis | Refractory arthritis | Anakinra/3 months | Tocilizumab |
Patient 7 | 49 | M | M694 V homozygous | Amyloidosis Stage 4 CRD 2.5 g/day proteinuria | İncrease of proteinuria | Canakinumab/4 months | Tocilizumab |
Patient 8 | 45 | F | M694 V heterozygous | Side effect | Anakinra/2 years | Multiple sclerosis-drug stop |